Achillion Pharmaceuticals (ACHN) has risen sharply, recording gains of 2.82% in the past 4 weeks. However, the stock has corrected -4.16% in the past 1 week, providing a good buying opportunity on dips. Achillion Pharmaceuticals (ACHN) : During the past 4 weeks, traders have been relatively bearish on Achillion Pharmaceuticals (ACHN), hence the stock is down -1.49% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -5.57% relative to the S&P 500. The stock has recorded a 20-day Moving Average of 3.76% and the 50-Day Moving Average is 1.22%.
Achillion Pharmaceuticals (NASDAQ:ACHN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $8.70 and $8.62 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $8.85. The buying momentum continued till the end and the stock did not give up its gains. It closed at $8.76, notching a gain of 1.39% for the day. The total traded volume was 1,538,587 . The stock had closed at $8.64 on the previous day.
The company Insiders own 6.52% of Achillion Pharmaceuticals shares according to the proxy statements. Institutional Investors own 81.98% of Achillion Pharmaceuticals shares. In a related news,The officer (Chief Financial Officer) of Achillion Pharmaceuticals Inc, Fenton Mary Kay sold 43,500 shares at $10.08 on December 28, 2015. The Insider selling transaction had a total value worth of $438,480. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.